- /
- Supported exchanges
- / US
- / VTYX.NASDAQ
Ventyx Biosciences Inc (VTYX NASDAQ) stock market data APIs
Ventyx Biosciences Inc Financial Data Overview
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ventyx Biosciences Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ventyx Biosciences Inc data using free add-ons & libraries
Get Ventyx Biosciences Inc Fundamental Data
Ventyx Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -116 438 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: -0.45
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ventyx Biosciences Inc News
New
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines(NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade. What happened Accord...
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
On February 13, 2026, Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics(NASDAQ:APGE), an estimated $3.87 million trade based on quarterly average pricing. What happ...
Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.
Wall Street tends to latch onto exciting stories. Sometimes, however, investors are so nearsighted that they forget to consider the long-term picture. That's what could be taking place with Eli Lilly(...
Halper Sadeh LLC is Investigating STEL, CWBC, SKYT, VTYX on Behalf of Shareholders
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.